© Reuters.
NEW YORK – Viatris Inc (NASDAQ:). and Theravance Biopharma (NASDAQ:) have announced successful results from a Phase III trial for YUPELRI (revefenacin) conducted in China, involving 258 patients with moderate to severe chronic obstructive pulmonary disease (COPD). The study demonstrated a significant improvement in lung function over a 12-week period, as measured by trough forced expiratory volume in one second (FEV1) when compared to a placebo.
The positive outcomes from the trial are a promising development for COPD treatment, as they mirror findings from similar studies conducted in the United States. The trial’s success paves the way for a planned regulatory submission in China by mid-2024. Both companies have expressed their commitment to addressing the needs of COPD patients, who are part of a demographic contributing to China’s annual healthcare costs totaling $266 billion.
Rajiv Malik, President of Viatris, and Rick E Winningham, CEO of Theravance Biopharma, jointly praised the efficacy and safety profile of YUPELRI. They conveyed optimism for the potential impact on COPD patients’ quality of life. The collaboration between the two pharmaceutical firms is aimed at developing and commercializing nebulized revefenacin products designed to treat COPD and other respiratory ailments.
This announcement marks a significant milestone for Viatris and Theravance Biopharma as they continue to advance their respiratory care portfolio, offering new therapeutic options for patients with respiratory diseases.
InvestingPro Insights
Given the recent success of Viatris Inc. and Theravance Biopharma in their Phase III trial for YUPELRI, it’s worth considering some key InvestingPro metrics and tips for these companies.
For Viatris, the InvestingPro Tips reveal that the company has been aggressively buying back shares, showing confidence in its own value. It also has consistently increasing earnings per share and pays a significant dividend to shareholders, which may be appealing to investors. However, it’s important to note that three analysts have revised their earnings downwards for the upcoming period. Relevant InvestingPro Data for Viatris includes a market cap of 10.77B USD, a P/E ratio of 5.98, and a dividend yield of 5.22%.
In the case of Theravance Biopharma, the InvestingPro Tips suggest that the company holds more cash than debt on its balance sheet and its liquid assets exceed short term obligations, indicating financial stability. However, analysts do not anticipate the company will be profitable this year. The InvestingPro Data for Theravance Biopharma shows a market cap of 502.46M USD, a negative P/E ratio of -9.91, and a revenue growth of 5.55%.
For a more comprehensive view of these companies’ financials and future prospects, consider exploring the additional tips and data available on InvestingPro.
Remember, these InvestingPro Tips are just a few of the many available when you subscribe to InvestingPro. Get access to more valuable insights to make informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
